Pulmonx strives to improve the lives of patients suffering from emphysema with its minimally-invasive, personalized technologies for interventional pulmonology.

Our portfolio includes the Zephyr Endobronchial Valve(1), the most-studied device for endoscopic lung volume reduction and the Chartis System(2), a proprietary diagnostic that identifies collateral ventilation. Used together, these technologies have been proven to improve pulmonary function, exercise capacity and quality of life in emphysema patients across multiple randomized controlled trials and in 12,000 patients worldwide. In fact, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) now includes endobronchial valves in its management recommendations for Chronic Obstructive Pulmonary Disease (COPD)1.

The StratX Lung Analysis Platform(3), a cloud-based quantitative computed tomography (CT) analysis service is actually offered in Europe. StratX is designed to work in combination with the Chartis System to identify responders and non-responders for the Zephyr valve.

AeriSeal(4) is available in a limited release in selected centers in Europe, a foam-based lung sealant that is expected to significantly expand the treatable patient population for the company’s therapies.

The company is invested in building further clinical evidence across patient phenotypes to support the use of its technologies.

Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. In the United States,the Zephyr Endobronchial Valve is an investigational device and the Chartis Sytem is FDA cleared.

  2017 Landmark data from 2 Multicenter RCTs presented showing substantial clinical benefits for both heterogeneous and homogeneous emphysema patients without collateral ventilation.
  2016 GOLD includes Zephyr EBV in its COPD management recommendations
  Respiration publishes positive 1-year outcomes from STELVIO, 1st Zephyr RCT using Chartis for patient selection
  American Journal of Respiratory and Critical Care Medicine publishes results from IMPACT, 1st Zephyr multicenter RCT in patients with homogeneous emphysema using Chartis for patient selection
  StratX Lung Analysis Platform launched
  2015 10,000+ patients treated and 90+ publications
  New England Journal of Medicine publishes positive 6-month results from STELVIO
  The Lancet publishes 1st successful sham-controlled trial of any minimally invasive emphysema device (Zephyr), BeLieVeR-HIFi
  2014 Acquisition of Aeris Therapeutics assets, including AeriSeal
  2013 European Respiratory Journal publishes Chartis multicenter trial demonstrating ability to predict Zephyr responders
  2011 European Respiratory Journal publishes 5-year data showing Zephyr sustained benefits and potential survival benefit
  2010 New England Journal of Medicine publishes 1st randomized trial of Zephyr
  2009 Chartis System receives CE Mark
  2003 Zephyr receives CE Mark
  2001 1st in man implant of Zephyr valve

 

1 GOLD (Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of COPD – 2017 report.
CAUTION: (1) The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use. (2) The Chartis System is FDA cleared. (3),(4) StratX and AeriSeal® System are not available in the US.